Tuesday 16 August 2022 - 02:25
In Business 42 Years - Since 1980
PLEASE NOTE: During August 2022 we are doing a comprehensive revision of our customer service workflow. This includes training of current and new personnel. We are expecting that these changes will have only very minimal effects on our overall order processing and shipping activities. However, we do ask any customers who prefer that their shipments go out on Fridays to contact our Customer Service group and let them know about your preferences in advance. Thank you.
Reminder: Genuine LC Laboratories® brand PMA, which we have been manufacturing in the U.S. for more
than 40 years, is available directly from us: Cat No. P-1680 Phorbol 12-Myristate 13-Acetate, >99.5%.
Our PMA is also available from our >50 U.S. and international distributors, and from more than a dozen
major biochemical reagent "resellers" (who sell our PMA under their own brand names and labels)
FREE SHIPPING TO THE U.S. AND 32 OTHER COUNTRIES! [Read more].
E-4040 Everolimus, >99%
Synonyms : [RAD001] [SDZ-RAD]
Related Terms : [Afinitor] [Certican] [Zortress]
- Size
- US $
- €
- £
- ¥
- 5 mg
- 34
- 33
- 28
- 4,500
- In stock
- 10 mg
- 57
- 55
- 47
- 7,600
- In stock
- 25 mg
- 89
- 87
- 73
- 11,800
- In stock
- 50 mg
- 135
- 132
- 111
- 17,900
- Add to Cart
- Out of stock
- 100 mg
- 164
- 160
- 135
- 21,800
- Add to Cart
- Out of stock
- 250 mg
- 346
- 339
- 286
- 45,900
- Add to Cart
- Out of stock
- 500 mg
- 543
- 532
- 449
- 72,000
- Add to Cart
- Out of stock
- 1 g
- 934
- 915
- 772
- 123,900
- Add to Cart
- Out of stock
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
- M.W. 958.22
- C53H83NO14
- [159351-69-6]
- M.I. 14: 3907
Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 100 mg/mL; soluble in ethanol at 100 mg/mL; very poorly soluble in water; maximum solubility in plain water is estimated to be about 1-10 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A.
- More than 525 labs worldwide have purchased Everolimus from LC Labs (either directly from us or from our many distributors, many of whom resell under their own labels).
- Everolimus is an immunosuppressant analog of rapamycin (sirolimus) and inhibits growth factor-mediated proliferation of haematopoietic and nonhaematopoietic cells. Chapman, T.M. and Perry, C.M. "Everolimus." Drugs 64: 861-874 (2004).
- Everolimus shows a potent inhibitory effect on posttransplant lymphoproliferative disorder (PTLD)-derived cells in vitro and in vivo, in a dose range that can prevent allograft rejection, and may demonstrate activity in both the prevention and treatment of PTLDs in transplant patients. Majewski, M., et al. "Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses." Transplantation 75: 1710-1717 (2003).
- Oral everolimus inhibits in-stent neointimal growth in the rabbit iliac artery. Everolimus was well tolerated at a dose of 1.5 mg/kg given 1 day before stenting followed by 0.75 mg/kg per day for 28 days and was related with significant neointimal healing. Farb, A., et al. "Oral Everolimus Inhibits In-Stent Neointimal Growth." Circulation 106: 2379-2384 (2002).
- Everolimus is the active ingredient in the drug product sold under the trade names Afinitor®, Certican®, and Zortress® and in the drug-eluting stent sold under the tradename XienceV®. This drug has been approved in at least one country for prophylaxis of organ rejection in patients who have received a kidney or heart transplant, and the stent has been approved in at least one country for use in patients undergoing angioplasty. NOTE: THE EVEROLIMUS SOLD BY LC LABORATORIES FOR RESEARCH IS NOT AFINITOR®, CERTICAN®, ZORTRESS®, AND XIENCE V®, AND IS NOT FOR HUMAN USE.
- Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
- This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
- Not available in some countries; not available to some institutions; not available for some uses.
- Please see also our other standard immunosuppressant products:
A-1040 Ascomycin
C-6000 Cyclosporin A
F-4633 Fingolimod Hydrochloride Salt
F-4900 FK-506
R-5000 Rapamycin
T-8040 Temsirolimus
T-1377 Tofacitinib, Free Base
T-1399 Tofacitinib,Citrate
